In This Article:
CARLSBAD, Calif., May 06, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025.
The agenda for the event is as follows:
-
5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders
-
All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2025.
-
Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required to log-in, vote and submit questions during the webcast
-
Ionis does not provide proxy cards or have access to proxy card information, including 16-digit control numbers. For help obtaining a proxy card, locating your control number or for instructions to access the webcast, stockholders of record should contact their brokerage firm before Thursday, May 22.
-
A help line will be available on the registration page of the live webcast for participants requiring technical assistance in accessing or participating during the live event. There will not be a replay of this session.
-
-
5:30 p.m. ET (2:30 p.m. PT) – Virtual corporate update
-
Brett P. Monia, Ph.D., Ionis’ chief executive officer, will provide a general corporate update.
-
The presentation will be followed by a question-and-answer session. Instructions on how to submit the questions will be shared at the beginning of the session.
-
All interested parties may access the webcast live at https://event.webcasts.com/starthere.jsp?ei=1712421&tp_key=7d89cf170d. An archived replay of the webcast will be posted for a limited time following the meeting at that same address.
-
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.